Company profile: Alltranz
June 16, 2009
AllTranz is a Pharmaceutical startup based in Lexington. Audra Stinchcomb is a professor at UK and is the founder.
What is your 30 second elevator pitch?
AllTranz will be a leader in the development of innovative pharmaceutical products delivered via unique dermal solutions to treat a variety of neuroscience disorders. AllTranz leverages proprietary technology to modify existing chemical entities with proven clinical outcomes to produce important new pharmaceutical products that extend patent franchises.
What Stage of development are you at? what do the next 12-18 months look like?
In order to take the lead product through Phase II Clinical Trials in 2011, the Company anticipates a total funding of approximately $20 million. We believe that the Company will have a range of exit opportunities after it attains seminal milestones, such as completion of Phase II Clinical Trials, post the $20 million investment. With a pipeline of innovative products, we believe that AllTranz will have a range of exit opportunities, including potential licensing, partnering or an IPO, as well as the revenue stream generated through the launch of the lead product in 2015. The total financing sought at this time is $8 to $10 million dollars in order to complete the lead product Phase I Clinical Trial and move two other products through preclinical toxicology testing.
What funding/growth have you had to date?
We have raised over $1.2 million from the Bluegrass Angels, Kentucky Seed capital fund, Commonwealth seed fund and others. Our lead product is a proprietary synthetic cannabinoid for moderate to severe pain delivered via gel. The initial indication for the lead product is for the treatment of osteoarthritis.
